SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported)
September 24, 1999
GISH BIOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
California
(State of other jurisdiction of incorporation or organization)
0-10728 95-3046028
(Commission File Number) (I.R.S. Employer Identification Number)
2681 Kelvin Avenue
Irvine, California 92614
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code
(949) 756-5485
Item 5. Other Events
On September 24, 1999, the Company announced a 23 percent reduction in its work
force, with the objective of reducing operating costs. Severance costs related
to the reduction in personnel of approximately $100,000 are expected to be
charged to operations in the quarter ending September 30, 1999.
Item 7. Exhibits
Exhibit No. Description
- ---------- -----------
99.1 Press Release Dated September 24, 1999
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Gish Biomedical, Inc.
-----------------------------
(Registrant)
By /s/ JAMES R. TALEVICH
-----------------------------
James R. Talevich
Vice President/CFO
Date September 30, 1999
-----------------------------